Sexual Health Impact of Using Pre-exposure HIV Prophylaxis

Completed

• Conditions: Pre-exposure HIV Prophylaxis (PrEP)

• Registration Number: NCT05269199
• Lead Sponsor: University Hospital, Clermont-Ferrand

Brief Summary

Epidemiological and psychosociological survey of people on pre-exposure HIV prophylaxis (PrEP).

Detailed Description

This study is perform to study the sexual health satisfaction of men who have sex with men (MSM), since the use pre-exposure HIV prophylaxis (PrEP), compared to the time before PrEP.

Study Timeline

• Status Verified: 2021-10
• Study First Submitted: 2022-02-25
• Study First Submitted QC: 2022-02-25
• Study First Posted: 2022-03-07
• Study Start: 2022-04-01
• Primary Completion: 2022-09-12
• Study Completion: 2023-03-12
• Last Update Submitted: 2023-04-28
• Last Update Posted: 2023-05-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 56

Inclusion Criteria

• Adult patient, male having sex with men, not infected with HIV, and using HIV prophylaxis by pre-exposure treatment (PrEP) for at least 1 year, received in consultation for renewal of this prescription.
• Able to give his non-opposition to participate in the research.
• Affiliation to a social security scheme.

Exclusion Criteria

• Patient under curatorship/guardianship or safeguard of justice
• Refusal to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sexual health satisfaction	1 day during the scheduled consultation	To study the sexual health satisfaction of men who have sex with men (MSM), since the use of HIV prophylaxis by pre-exposure treatment (PrEP), compared to the time before PrEP.

Secondary Outcome Measures

Name	Time	Method
Sentimental satisfaction	1 day during the scheduled consultation	To study the sentimental satisfaction since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
Risky behaviours	1 day during the scheduled consultation	To study risky behaviours without, then on PrEP since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
Specific care	1 day during the scheduled consultation	Describe the use of specific care during PrEP.
Predictors of satisfaction	1 day during the scheduled consultation	Define possible predictors of satisfaction with PrEP.

Trial Locations

Locations (7)

CEGIDD Clermont Ferrand; 🇫🇷 Clermont-Ferrand, France

CHU Clermont-Ferrand; 🇫🇷 Clermont-Ferrand, France

CH Le Puy en Velay; 🇫🇷 Le Puy-en-Velay, France

CH Brioude; 🇫🇷 Brioude, France

CH Montluçon; 🇫🇷 Montluçon, France

CH Moulins; 🇫🇷 Moulins, France

CH Vichy; 🇫🇷 Vichy, France